GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » PS Ratio
中文

Vanda Pharmaceuticals (Vanda Pharmaceuticals) PS Ratio

: 1.43 (As of Today)
View and export this data going back to 2006. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vanda Pharmaceuticals's share price is $4.785. Vanda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.35. Hence, Vanda Pharmaceuticals's PS Ratio for today is 1.43.

The historical rank and industry rank for Vanda Pharmaceuticals's PS Ratio or its related term are showing as below:

VNDA' s PS Ratio Range Over the Past 10 Years
Min: 0.93   Med: 4.04   Max: 16.71
Current: 1.42

During the past 13 years, Vanda Pharmaceuticals's highest PS Ratio was 16.71. The lowest was 0.93. And the median was 4.04.

VNDA's PS Ratio is ranked better than
88.82% of 993 companies
in the Biotechnology industry
Industry Median: 8.93 vs VNDA: 1.42

Vanda Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $0.79. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.35.

Warning Sign:

Vanda Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Vanda Pharmaceuticals was -25.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -9.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.30% per year.

During the past 13 years, Vanda Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 90.40% per year. The lowest was -9.40% per year. And the median was 8.10% per year.

Back to Basics: PS Ratio


Vanda Pharmaceuticals PS Ratio Historical Data

The historical data trend for Vanda Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.96 2.92 3.32 1.66 1.26

Vanda Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.66 1.52 1.59 1.18 1.26

Competitive Comparison

For the Biotechnology subindustry, Vanda Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's PS Ratio falls into.



Vanda Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Vanda Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=4.785/3.348
=1.43

Vanda Pharmaceuticals's Share Price of today is $4.785.
Vanda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Vanda Pharmaceuticals  (NAS:VNDA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Vanda Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Executives
Joakim Wijkstrom officer: SVP, Chief Marketing Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran officer: VP, Acting CFO & Treasurer C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams officer: SVP & General Counsel C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos director, officer: Chief Executive Officer 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks officer: SVP, Business Development 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins director 1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones officer: Chief Corp. Affairs Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos director 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan director 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly officer: SVP, CFO, Treasurer & Secretar C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi officer: SVP, General Manager Europe 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Headlines